Mechanism of action<unk>  is a whole monoclonal antibody of isotype IgG1 that binds to the programmed death-ligand 1 (PD-L1) and therefore inhibits binding to its receptor programmed cell death 1 (PD-1). Formation of a PD-1/PD-L1 receptor/ligand complex leads to inhibition of CD8+ T cells, and therefore inhibition of an immune reaction. Immunotherapy aims at ceasing this immune blockage by blocking those receptor ligand pairs. In the case of<unk> , the formation of PD-1/PDL1 ligand pairs is blocked and CD8+ T cell immune response should be increased. PD-1 itself has also been a target for immunotherapy. Therefore,<unk>  belongs to the group of immune checkpoint blockade cancer therapies.
Avelumab
Alirocumab
Emapalumab
Anifrolumab
Burosumab
Evolocumab
Secukinumab
Olaratumab